Active Ingredient History
Fasudil (INN) is a potent Rho-kinase inhibitor and vasodilator. Since it was discovered, it has been used for the treatment of cerebral vasospasm, which is often due to subarachnoid hemorrhage, as well as to improve the cognitive decline seen in stroke patients. It has been found to be effective for the treatment of pulmonary hypertension. It has been demonstrated that fasudil could improve memory in normal mice, identifying the drug as a possible treatment for age-related or neurodegenerative memory loss. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Amyotrophic Lateral Sclerosis (Phase 2)
Atherosclerosis (Phase 2)
Cardiovascular Diseases (Phase 2)
Carotid Stenosis (Phase 2)
Corticobasal Degeneration (Phase 2)
Dementia (Phase 2)
Hypercholesterolemia (Phase 2)
Macular Edema (Phase 3)
Raynaud Disease (Phase 3)
Retinal Vein Occlusion (Phase 2/Phase 3)
Retinopathy of Prematurity (Phase 2/Phase 3)
Scleroderma, Systemic (Phase 3)
ST Elevation Myocardial Infarction (Phase 4)
Supranuclear Palsy, Progressive (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue